Mutations of the mitochondrial genome (mtDNA) underlie a substantial portion of mitochondrial disease burden. These disorders are currently incurable and effectively untreatable, with heterogeneous penetrance, presentation and prognosis. To address the lack of effective treatment for these disorders, we exploited a recently developed mouse model that recapitulates common molecular features of heteroplasmic mtDNA disease in cardiac tissue: the m.5024C> T tRNA Ala mouse. Through application of a programmable nuclease therapy approach, using systemically administered, mitochondrially targeted zinc-finger nucleases (mtZFN) delivered by adeno-associated virus, we induced specific elimination of mutant mtDNA across the heart, coupled to a reversion of molecular and biochemical phenotypes. These findings constitute proof of principle that mtDNA heteroplasmy correction using programmable nucleases could provide a therapeutic route for heteroplasmic mitochondrial diseases of diverse genetic origin.
Mutations of the mitochondrial genome (mtDNA) underlie a substantial portion of mitochondrial disease burden. These disorders are currently incurable and effectively untreatable, with heterogeneous penetrance, presentation and prognosis. To address the lack of effective treatment for these disorders, we exploited a recently developed mouse model that recapitulates common molecular features of heteroplasmic mtDNA disease in cardiac tissue: the m.5024C> T tRNA Ala mouse. Through application of a programmable nuclease therapy approach, using systemically administered, mitochondrially targeted zinc-finger nucleases (mtZFN) delivered by adeno-associated virus, we induced specific elimination of mutant mtDNA across the heart, coupled to a reversion of molecular and biochemical phenotypes. These findings constitute proof of principle that mtDNA heteroplasmy correction using programmable nucleases could provide a therapeutic route for heteroplasmic mitochondrial diseases of diverse genetic origin.
Mitochondrial diseases are a broad group of hereditary, multisystem disorders, a substantial portion of which are transmitted through mutations of mitochondrial DNA (mtDNA) with a minimum prevalence of 1 in 5,000 adults 1 . Human mtDNA is a small, double-stranded, multicopy genome present at ~100-10,000 copies per cell 2 . In the disease state, mutated mtDNA often co-exists with wild-type mtDNA in heteroplasmy, and disease severity in conditions caused by heteroplasmic mtDNA mutations correlates with mutation load 3 . A threshold effect, where > 60% mutant mtDNA load must be exceeded before symptoms manifest, is a definitive feature of heteroplasmic mtDNA diseases, and attempts to shift the heteroplasmic ratio below this threshold have driven much research towards treatment of these incurable and essentially untreatable disorders. One such approach relies on directed nucleolysis of mtDNA using, among other programmable genome engineering tools, mitochondrially targeted zinc-finger nucleases (mtZFNs) [4] [5] [6] 7 . Because mammalian mitochondria lack efficient DNA double-strand break repair pathways 8 , the selective introduction of double-strand breaks into mutant mtDNA leads to rapid degradation of these molecules by components of the mtDNA replisome 9 . As mtDNA copy number is maintained at a cell-typespecific steady-state level, selective elimination of mutant mtDNA stimulates replication of the remaining mtDNA pool, eliciting shifts in the heteroplasmic ratio.
In previous work, we have described methods for the delivery of zinc-finger proteins (ZFPs) to mitochondria in cultured cells 10, 11 and the assembly and function of efficient mtZFN architectures that are capable of producing large heteroplasmic shifts that result in phenotype rescue of patient-derived cell cultures 5, [12] [13] [14] . Using the first available mouse model of heteroplasmic mitochondrial disease, bearing the point mutation m.5024C> T in mitochondrial tRNA Ala (mt-tRNA Ala ), which faithfully recapitulates key molecular features of mitochondrial disorders in cardiac tissue 15 , we now demonstrate efficient manipulation of mtDNA heteroplasmy with concomitant rescue of molecular and biochemical phenotypes across the heart following the delivery of mtZFNs by systemically administered adeno-associated virus (AAV).
In the context of second-generation tail-tail mtZFN architectures that were shown to be efficacious in previous work 5, 16 , we set out to generate pairs of ZFPs with single-nucleotide-binding specificity for m.5024C> T. As this site in the mouse mtDNA is challenging for ZFPs, a selection of targeting strategies with varying numbers of zinc-finger motifs, spacer region lengths and additional linkers were used. The assembly of candidate ZFPs yielded a library (Supplementary Fig. 1a and Supplementary Table 1 ) consisting of 24 unique ZFPs targeting the m.5024C> T site, referred to as mutantspecific monomer (MTM), and a single partner ZFP targeting an adjacent sequence on the opposite strand, referred to as wild-typespecific monomer 1 (WTM1). These constructs were subjected to several rounds of screening in mouse embryonic fibroblasts (MEFs) bearing ~65% m.5024C> T heteroplasmy to assess specific heteroplasmy-shifting activity ( Supplementary Fig. 1b ). These screens identified consistent, specific activity of pairing MTM25/ WTM1 ( Fig. 1a and Supplementary Fig. 1c ), which produced a shift of ~20%, from 65% to 45% m.5024C> T heteroplasmy in the MEF cell line as determined by pyrosequencing ( Fig. 1b ). We also confirmed exclusive mitochondrial localization of MTM25 and WTM1 in MEF cells ( Supplementary Fig. 2 ) and then selected this pair for in vivo experiments.
MTM25 and WTM1 mtZFN monomers were encoded in separate viral genomes and encapsidated within the cardiotropic, engineered AAV9.45 serotype 17 (Fig. 1c ). Following tail-vein administration of 5 × 10 12 viral genomes per monomer per mouse, robust expression of MTM25 and WTM1 in total mouse heart tissue was detected by western blotting (Fig. 1d ). Despite equal quantities of injected viral genomes, lower expression levels of WTM1 Letters NATuRe MeDiCiNe were consistently detected, possibly due to lower stability of the translated protein. Next, various doses of mtZFN-AAV9.45 were administered to mt-tRNA Ala animals harboring m.5024C> T heteroplasmy ranging from 44% to 81% (Supplementary Table 2 ). As only minimal variance in heteroplasmy is observed between tissues of the m.5024C> T mouse 14 , mtDNA heteroplasmy is assessed by comparison of pyrosequencing data, expressed as the change (Δ ) between the ear punch genotype (E) determined at 2 weeks of age (prior to experimental intervention) and the post-mortem heart genotype (H). Analysis of animals at 65 days post-injection revealed specific elimination of the m.5024C> T mutant mtDNA in mtZFNtreated mice, but not in vehicle-injected or single-monomerinjected controls (Fig. 1e ). The extent to which heteroplasmy was altered by mtZFN treatment followed a biphasic AAV dose-dependent trend, with the intermediate dose (5 × 10 12 viral genomes) being the most efficient in eliminating m.5024C> T mutant mtDNA (Fig. 1e ). The lowest (1 × 10 12 viral genomes) dose did not result in heteroplasmy shifts ( Fig. 1e ), owing to an insufficient concentration of mtZFNs and mosaic transduction of the targeted tissue by AAV ( Supplementary Fig. 3 ). The highest dose (1 × 10 13 viral genomes) exhibited diminished heteroplasmy-shifting activity compared with the intermediate dose (5 × 10 12 viral genomes), probably due to mitochondrial off-target effects, resulting in partial mtDNA copy number depletions, which are not observed when lower doses are administered ( Fig. 1f ). It is unclear what effect, if any, these partial depletions of mtDNA copy number could exert over time; however, 13 . The change in m.5024C> T heteroplasmy is plotted. utZFN is a mtZFN that does not have a target site in mouse mtDNA 13 . Concentration '-' and '+ ' refer to zero and maximum concentration, respectively. n = 5 (mtZFN, low expression), n = 8 (mtZFN, high expression) and n = 4 (all other conditions) biologically independent cell cultures. The error bars indicate the s.d. Statistical analysis was performed using the two-tailed Student's t-test. Vehicle/mtZFN low expression: P = 0.000021; vehicle/mtZFN high expression: P = 0.000083. Gray bars indicae the mean. c, Scheme of in vivo experiments. MTM25 and WTM1 are encoded in separate AAV genomes, encapsidated in AAV9.45 then simultaneously administered by tail-vein (TV) injection. Animals are euthanized at 65 days post-injection. d, Western blot of total heart protein from animals injected with 5 × 10 12 viral genomes of MTM25 and/or WTM1. Both proteins include the HA tag and are differentiated by molecular weight. This blot was performed twice with similar results. The raw data are available for this panel ( Supplementary Fig. 9 ). CBB, Coomassie Brilliant Blue. e, Pyrosequencing of m.5024C> T heteroplasmy from ear (E) and heart (H) total DNA. The change in m.5024C> T is plotted. n = 20 (vehicle), n = 3 (WTM1 only) and n = 4 (all other conditions) animals (Supplementary Table 2 ). The error bars indicate the s.e.m. Statistical analysis was performed using the two-tailed Student's t-test. Vehicle/intermediate dose: P < 0.00001; vehicle/high dose: P < 0.00001. Gray bars indicate the mean. AAV '-' and '+ ' refer to zero and maximum dose, respectively. f, Assessment of mtDNA copy number by quantitative PCR. n = 8 (vehicle) and n = 4 (all other conditions) animals (Supplementary Table 2 ). The center line is the mean and the error bars indicate the s.e.m. Statistical analysis was performed using the two-tailed Student's t-test; P = 0.007931. Central black line indicates the mean. ** indicates P < 0.01, *** indicates P < 0.001. this lattermost result is consistent with our previous observations 13 , underscoring the importance of fine-tuning mtZFN levels in mitochondria for efficient mtDNA heteroplasmy modification. AAV9.45 transduction could not be detected in non-cardiac tissues, and no shifts in heteroplasmy were detected in the liver at 65 days post-injection, irrespective of viral dose ( Supplementary Fig. 3 ). As AAV transduction of post-mitotic tissues, particularly in shortlived mammals, is essentially permanent, a time dependence of heteroplasmy shifting is expected. Accordingly, measurements of mtDNA heteroplasmy over time in cardiac tissue demonstrate significant increases in heteroplasmy-shifting activity in the latest post-treatment time points ( Supplementary Fig. 4 ). Despite the presence of two regions with significant homology to the mtDNA target site in the nuclear genome, no evidence for off-target effects exerted by mtZFNs could be detected at these sites ( Supplementary  Fig. 5a ,b), consistent with our previous reports of exclusive mitochondrial localization of mtZFNs 5,10,11,13 . In addition, no evidence for non-homologous end-joining at the target site in mtDNA could be detected, confirming previous data that mtZFN-induced DNA double-strand breaks do not result in non-homologous end-joining activity 13 ( Supplementary Fig. 5c ).
Having defined conditions within which a robust shift of m.5024C> T heteroplasmy is achieved in vivo, we next addressed disease-relevant phenotype correction in the model. A common feature of mt-tRNA mutations in mitochondrial diseases, recapitulated in the tRNA Ala mouse model 15 , is the instability of mt-tRNA molecules in proportion to mutant load 18 ( Fig. 2a ). To assess the effects of mtZFN treatment on the stability of mt-tRNA Ala in the hearts of animals across the dosage range, we used high-resolution northern blotting, which revealed a significant increase in mt-tRNA Ala steady-state levels ( Fig. 2b and Supplementary Fig. 6 ) proportional to the heteroplasmy shifts detected in these mice (average m.5024C> T heteroplasmy: control, 71% pre-treatment and 73% post-treatment; low AAV dose, 73% pre-treatment and 71% post-treatment; medium AAV dose, 73% pre-treatment and 37% post-treatment; high AAV dose, 71% pre-treatment and 40% Given the nature and position of this mutation, transcribed tRNA molecules containing the mutation mispair are unlikely to fold correctly or be aminoacylated, resulting in reduced steady-state levels of mt-tRNA Ala at high levels of m.5024C> T heteroplasmy 15 . b, Quantification of high-resolution northern blot data from total heart RNA extracts. mt-tRNA Ala and mt-tRNA Cys abundance was normalized to 5S rRNA. n = 8 (vehicle) and n = 4 (all other conditions) animals (Supplementary Table 2 
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NATuRe MeDiCiNe post-treatment) ( Fig. 1e and Supplementary Table 2 ) and consistent with previously reported data 15 . Depletions of mtDNA copy number associated with the administration of high viral doses ( Fig. 1f ) did not seem to affect the recovery of mt-tRNA Ala steady-state levels following heteroplasmy shift (Fig. 2b ). This agrees with previously published data that even severe mtDNA depletion does not manifest in proportional changes of mitochondrial RNA steady-state levels 19 .
To assess the physiological effects of mt-tRNA Ala molecular phenotype rescue, we compared steady-state metabolite levels in cardiac tissue from mice with high m.5024C> T mutant heteroplasmy treated with the intermediate viral titer (5 × 10 12 viral genomes) with heteroplasmy-matched and age-matched controls (Supplementary Table 2 ). This analysis revealed an altered metabolic signature in mtZFN-treated mice compared with controls ( Fig. 2c and Supplementary Fig. 7) , demonstrating significantly increased pyruvate levels ( Fig. 2d ) and significantly decreased lactate levels ( Fig. 2e ), suggestive of a diminished reliance on glycolysis, coupled to increased aspartate levels (Fig. 2f) , suggestive of improved mitochondrial respiration, in the treated mice 20 . These indicators of improved mitochondrial metabolism are not observed in mice treated with the highest AAV dose ( Supplementary Fig. 8 ), which also exhibit substantial copy number depletions (Fig. 1f ). Owing to phenotypic heterogeneity of mice bearing high levels of mtDNA heteroplasmy, changes in gross cardiac function following heteroplasmic shifts could not be assessed. Taken together, these data indicate that partial m.5024C> T heteroplasmy shifts ( Fig. 1e ) result in the recovery of mt-tRNA Ala steady-state levels and the rescue of mitochondrial function (Fig. 2b-f ).
Our previous reports on the use of mtZFN technology have demonstrated that these programmable nucleases can target multiple genetic lesions, producing phenotypically relevant shifts of mtDNA heteroplasmy in cellular models of mitochondrial dysfunction 5, 13, 14 . Here, we have further demonstrated the flexibility and future potential of mtZFN technology by targeting another heteroplasmic mutation in mouse mtDNA, m.5024C> T, manipulating the heteroplasmy of this variant both in vitro and in vivo ( Fig. 1) , which results in the molecular and physiological rescue of disease phenotypes in heart tissue (Fig. 2 ).
Despite the time elapsed since mtDNA mutations were first associated with human disease in the late 1980s 21, 22 , effective treatments for heteroplasmic mitochondrial disease have not been forthcoming. Preventing the transmission of mtDNA mutations through mitochondrial replacement therapy or mitochondrial donation has gained traction 23, 24 , although given the nature of the mtDNA bottleneck 25 , issues surrounding carryover of mutant mtDNA 26 , heterogeneous mitochondrial disease presentation 27 and the subsequent lack of family history of mitochondrial disease in the majority of new cases, these approaches can only be of limited use. More recently, several intriguing molecular pathways to treatment of mitochondrial disease have been defined and explored by numerous groups 28 ; however, hopes for clinically relevant therapy for heteroplasmic mitochondrial disease, thus far, remain unfulfilled 29 . The data that we describe in this Letter, and those from Bacman et al. 30 , constitute proof of principle that somatic mitochondrial genome editing using programmable nucleases, in combination with the ever-increasing collection of engineered, tissue-specific AAV serotypes, may offer a potentially universal route to treatment for heteroplasmic mitochondrial disease. Given the magnitude of in vivo heteroplasmy modification demonstrated using these tools, total amelioration of clinical symptoms and/or halting of disease progression could be expected. As such, this development has the potential to transform the prospects of many patients with mitochondrial disease, and further work enabling the translation of these tools into effective medicines is vital.
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Methods
Constructs, plasmids and viral vectors.
All mtZFN architectures used were as reported for second-generation mtZFN, with the exception of the ZFP domains 5, 16 . The MTM(n)_T2A_WTM1 m.5024C> T candidate library was cloned by the insertion of the MTM ZFP domains upstream of FokI(+ ) between 5′ EcoRI and 3′ BamHI restriction sites. This product was then PCR amplified to include a 5′ ApaI site and remove the 3′ stop codon while also incorporating a T2A sequence and 3′ XhoI site. This fragment was then cloned into pcmCherry (Addgene 62803) using ApaI/XhoI sites. The WTM1 ZFP was separately cloned upstream of FokI(-) in the pcmCherry_3k19 vector (Addgene 104499), incorporating the 3′ hammerhead ribozyme (HHR) using 5′ EcoRI and 3′ BamHI sites, and the resulting product was PCR amplified to include 5′ XhoI and 3′ AflII sites allowing cloning downstream of MTM(n) variants. MTM25(+ ) and WTM1(-) monomers were cloned into separate pcmCherry and pTracer vectors as described previously 16 . Vector construction of mtZFNs intended for AAV production was achieved by PCR amplification of MTM25(+ )_HHR and WTM1(-)_HHR transgenes, incorporating 5′ EagI and 3′ BglII sites. These products were then cloned into rAAV2-CMV between 5′ EagI and 3′ BamHI sites. The FLAG epitope tag of WTM1(-) was replaced with a hemagglutinin (HA) tag at the same position in the WTM1(-) open reading frame by PCR. The resulting plasmids were used to generate recombinant AAV2/9.45-CMV-MTM25 and AAV2/9.45-CMV-WTM1 viral particles at the UNC Gene Therapy Center, Vector Core Facility (Chapel Hill, NC, USA). The 3K19 HHR sequence 31 was incorporated into the mtZFN-AAV9.45 constructs to allow ubiquitous expression of the transgene from CMV while limiting the expression level, allowing the administration of the high viral titers required to ensure effective co-transduction of cells in the targeted tissue without inducing large mtDNA copy number depletions.
Maintenance, transfection and FACS of cell cultures.
Wild-type and m.5024C> T MEF cell lines were cultured in DMEM containing 2 mM l-glutamine, 110 mg l -1 sodium pyruvate (Life Technologies) and 10% FCS (PAA Laboratories). Cells were transfected by electroporation using Nucleofector II apparatus (Lonza) and a MEF1 kit and T20 program. FACS was performed as described previously 16 . Control of mtZFN expression was achieved through titration of tetracycline into culture media, controlling the rate of HHR autocatalysis as described previously 13 . Table 1 ). Treatments of vehicle (1× PBS, 350 mM NaCl and 5% w/v d-sorbitol) and AAVs were administered by tail-vein injection.
Protein extraction and quantitation. For cultured cells, total cellular protein was extracted as described previously 13 . For mouse heart tissue, 50 mg was homogenized in RIPA buffer (150 mM NaCl, 50 mM Tris, pH 8, 1% (v/v) Triton X-100, 0.5% (v/v) deoxycholate and 0.1% (v/v) SDS) using a gentleMACS dissociator (Miltenyi). The resulting homogenate was centrifuged at 10,000g at 4 °C for 10 min and the supernatant was then recovered and centrifuged at 10,000g at 4 °C for 10 min. The concentration of both cellular and tissue protein extracts was determined by bicinchonic acid (BCA) assay (Pierce).
Immunodetection of proteins. The localization of proteins by immunofluorescence in fixed MEF cells was performed as described previously 11 . The following antibodies were used: rabbit anti-TOM20 (1:200, sc-11415, Santa Cruz Biotechnology), Alexa Fluor 647 anti-rabbit (1:1,000, ab150079, Abcam), mouse anti-FLAG (1:1,000, F1804, Sigma), Alexa Fluor 594 anti-mouse (1:1,000, R37121, Life Technologies), rat anti-HA (1:200, 11867431001, Roche) and Alexa Fluor 488 anti-rat (A11006, Life Technologies). Immunofluorescence images were captured using a Zeiss LSM880 confocal microscope and processed using ImageJ. The detection of proteins by western blotting was achieved by resolving 20-100 μ g of extracted protein on SDS-PAGE 4-12% Bis-Tris Bolt gels. These were transferred to nitrocellulose using an iBlot 2 transfer cell (Life Technologies). The following antibodies were used for western blotting: rat anti-HA (1:500, 11867431001, Roche) and goat anti-rat horseradish peroxidase (1:1,000, SC2065, Santa Cruz). Gels were stained for loading using Coomassie Brilliant Blue (Life Technologies).
Tissue histology and fluorescence microscopy. To evaluate green fluorescent protein expression in histological sections, mouse tissues (the heart, liver, brain, kidney and skeletal muscles) were snap frozen in isopentane that was pre-cooled in liquid nitrogen. Sections (8-μ m thick) on positive-charged glass slides were fixed in 4% PFA, washed with PBS and finally mounted with Prolong Diamond Antifade Mountant with DAPI. Images were acquired using a Zeiss Axio Observer Z1 microscope LSM 880 confocal module, equipped with an argon ion multiline laser, solid-state diode laser (405 nm), AOTF filter and a plan-apochromat × 63/1.4 NA oil immersion objective. All settings were preserved during image acquisition for all samples. Image J was used to process the images.
DNA extraction and quantitation. DNA was extracted from both cultured cells and whole tissues using a Qiagen DNEasy Blood and Tissue kit, according to the manufacturer's instructions. Once acquired, DNA concentrations were assessed by spectrophotometry.
Pyrosequencing and quantitative PCR. Assessment of m.5024C> T mtDNA heteroplasmy was carried out by pyrosequencing. PCRs for pyrosequencing were prepared using KOD DNA polymerase (Takara) for 40 cycles using 100 ng template DNA with the following primers: m.4,962-4,986 forward 5′ ATACTAGTCCGCGAGCCTTCAAAG 3′ m.5,360-m.5,383 reverse 5′ [Btn] GAGGGTTCCGATATCTTTGTGATT 3′ m.5,003-m.5,022 sequencing primer 5′ AAGTTTAACTTCTGATAAGG 3′ mtDNA copy number of mouse heart samples was determined by quantitative PCR using PowerUp SYBR Green Master Mix according to the manufacturer's protocol (Applied Biosystems). Samples were analyzed using a 7900HT Fast Real-Time PCR System (Thermo Fisher). The following primers were used:
MT-COI forward 5′ TGCTAGCCGCAGGCATTACT 3′ MT-COI reverse 5′ CGGGATCAAAGAAAGTTGTGTTT 3′ RNaseP forward 5′ GCCTACACTGGAGTCCGTGCTACT 3′ RNaseP reverse 5′ CTGACCACACACGAGCTGGTAGAA 3′ All primers for pyrosequencing and quantitative PCR were designed using NCBI reference sequences GRCm38.p6 and NC_005089.1 for the C57BL/6J mouse nuclear and mitochondrial genomes, respectively.
Amplicon resequencing of nuclear DNA off-target sites. Two regions of the NCBI reference sequence for C57BL/6J nuclear DNA demonstrated significant homology (> 75% sequence identity) with the mtZFN target site in mtDNA. Amplicons containing these sites were obtained by PCR using primers listed below: Chromosome 2 forward 5′ GGGTTCCGATATCTTTGTGATTGG 3′ Chromosome 2 reverse 5′ GAGCATAAGCCATTGTTGTTCTG 3′ Chromosome 5 forward 5′ GACTACCTGAGCAAGGAGTC 3′ Chromosome 5 reverse 5′ CTACAGGAGATGGAGGACAC 3′ All primers were designed using NCBI reference sequence GRCm38.p6 for the C57BL/6J mouse nuclear genome. PCR amplicons were subjected to Nextera sample processing and the resulting libraries were assessed by 2 × 150-cycle paired-end sequencing using a MiSeq instrument (Illumina). Quality trimming and 3′ -end adapter clipping of sequenced reads were performed simultaneously with Trim Galore! (--paired) and aligned to GRCm38 using bowtie2. Only reads that contained the entire region of chromosome 5 (60,042,834-60,042,934) or chromosome 2 (22,589,909-22,590,009) were selected for counting with SAMtools (flagstat) and insertion/deletion count based on CIGAR string (I/D). All individual samples yielded > 10,000 reads per nucleotide.
Amplicon resequencing of the mtDNA target site. The region m.4,962-5,383, which was also used for the pyrosequencing analysis, was amplified by PCR using unbiotinylated primers. PCR amplicons were subjected to Nextera sample processing and the resulting libraries were assessed by 2 × 150-cycle pairedend sequencing using a MiSeq instrument (Illumina). Quality trimming and 3′ -end adapter clipping of sequenced reads were performed simultaneously with Trim Galore! (--paired) and aligned to GRCm38 using bowtie2. Only reads that contained the entire region m.4,994-5,094 were selected for counting with SAMtools (flagstat) and insertion/deletion count based on CIGAR string (I/D). All individual samples yielded > 10,000 reads per nucleotide.
RNA extraction and northern blotting. Total RNA was extracted from 25 mg mouse heart tissue using TRIzol (Ambion) by homogenization using a gentleMACS dissociator (Miltenyi). Northern blotting was performed as described previously 32 . Briefly, 5 µ g total RNA was resolved on a 10% (w/v) polyacrylamide gel containing 8 M urea. Gels were dry blotted onto a positively charged nylon membrane (Hybond-N + ), with the resulting membrane crosslinked by exposure to 254-nm UV light, 120 mJ per cm 2 . For tRNA probes, crosslinked membranes were hybridized with radioactively labeled RNA probes T7 transcribed from PCR fragments corresponding to appropriate regions of mouse mtDNA. 5S rRNA was probed with a complementary α -[ 32 P]-end-labeled DNA oligo. Membranes were exposed to a storage phosphor screen and scanned using a Typhoon phosphor imaging system (GE Healthcare). The signals were quantified using Fiji software. The following primers/oligonucleotides were used:
All primers for northern blotting were designed using NCBI reference sequences GRCm38.p6 and NC_005089.1 for the C57BL/6J mouse nuclear and mitochondrial genomes, respectively.
Sample preparation and liquid chromatography coupled to mass spectrometry analysis. Snap-frozen tissue specimens were cut and weighed into Precellys tubes prefilled with ceramic beads (Stretton Scientific). An exact volume of extraction solution (30% acetonitrile, 50% methanol and 20% water) was added to obtain 40 mg specimen per ml extraction solution. Tissue samples were lysed using a Precellys 24 homogenizer (Stretton Scientific). The suspension was mixed and incubated for 15 min at 4 °C in a Thermomixer (Eppendorf), followed by centrifugation (16,000g for 15 min at 4 °C). The supernatant was collected and transferred into autosampler glass vials, which were stored at − 80 °C until further analysis. Samples were randomized to avoid bias due to machine drift and processed blindly. Liquid chromatography coupled to mass spectrometry analysis was performed using a QExactive Orbitrap mass spectrometer coupled to a Dionex U3000 UHPLC system (Thermo Fisher Scientific). The liquid chromatography system was fitted with a Sequant ZIC-pHILIC column (150 × 2.1 mm) and a guard column (20 × 2.1 mm) from Merck Millipore and temperature maintained at 40 °C. The mobile phase was composed of 20 mM ammonium carbonate and 0.1% ammonium hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 200 µ l min -1 , with the gradient as described previously 33 . The mass spectrometer was operated in the full MS and polarity-switching mode. The acquired spectra were analyzed using XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Fisher Scientific).
Statistical analysis. One-tailed and two-tailed Student's t-tests were used to compare independent means. Statistical analysis was performed using Prism 5 software. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Sample size
A naive, preliminary power calculation was performed at the outset, using speculative effect sizes we hoped to observe. The effects observed were much larger than anticipated, so the number of animals used in the study was scaled back, in accordance with the three R's principle (replacement, reduction, refinement), enshrined in UK animal research laws.
Data exclusions No samples or data were excluded.
Replication
All experiments were subject to both biological and technical replicates to ensure reproducibility. The data described in the manuscript was collected from a number of independent experiments taking place over a ~3 year period.
Randomization Randomization was not necessary for this study. Male animals were assembled into cohorts based on similar age and heteroplasmy.
Homogeneity of the control and treatment cohorts (at the pre-treatment point) was the aim.
Blinding
Animals were given unique identifying numbers and the administration of substances was blinded. Samples for RNA, qPCR, amplicon resequencing and LC-MS analyses were blinded.
Reporting for specific materials, systems and methods 
Validation
All antibodies have been verified using a variety of species-specific (human, mouse) cellular models. Verification of specific detection has been determined through a mixture of microscopy, subcellular fractionation and protein expression/purification studies.
